SCHEMBL5226932

SCHEMBL5226932

CC(C)(C)c1ccc(C(=O)Nc2ccc(NS(C)(=O)=O)cc2C(=O)Nc2cccc(O)c2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 12/20 0.57
PPARG P37231 6/20 0.57
F10 P00742 1/20 0.54
HPGD P15428 1/20 0.54
PPARA Q07869 5/20 0.53
KCNK9 Q9NPC2 1/20 0.52
UQCRB P14927 1/20 0.52
TP53 P04637 1/20 0.52
THRB P10828 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
MEN1 O00255 2/20 0.52
RAB9A P51151 2/20 0.52
KMT2A Q03164 2/20 0.52
ALDH1A1 P00352 1/20 0.52
MAPK1 P28482 1/20 0.52
HTT P42858 1/20 0.52
PPARD Q03181 1/20 0.52
NPC1 O15118 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5223601 0.93 NR1H4 (0.58) NR1H4PPARGHPGDPPARAKCNK9
SCHEMBL5226947 0.83 NR1H4 (0.55) NR1H4PPARGF10PPARAKCNK9
SCHEMBL5225715 0.83 F10 (0.76) NR1H4PPARGF10HPGDPPARA
SCHEMBL5224325 0.82 NR1H4 (0.80) NR1H4PPARGPPARAKCNK9TP53
SCHEMBL5228051 0.82 RAB9A (0.70) F10SMN1; SMN2MEN1RAB9AKMT2A
SCHEMBL7292693 0.82 KCNK9 (0.75) NR1H4KCNK9TP53THRBSMN1; SMN2
SCHEMBL6169846 0.81 ESR1 (0.55) NR1H4PPARGF10PPARA
SCHEMBL6169988 0.80 MAP4K4 (0.53) NR1H4PPARGF10HPGDPPARA
SCHEMBL5226509 0.77 NR1H4 (0.57) NR1H4PPARGPPARAMEN1RAB9A
SCHEMBL7366501 0.76 F10 (0.47) NR1H4PPARGF10HPGDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1014962-A4 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 2007-06-27 EP disclosed
US-6605626-B2 Benzamide inhibitors of factor Xa ELI LILLY AND COMPANY 2003-08-12 US disclosed
US-20020120007-A1 Benzamide inhibitors of factor Xa BEIGHT DOUGLAS WADE (US) 2002-08-29 US disclosed
US-6313122-B1 AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS ELI LILLY AND COMPANY 2001-11-06 US disclosed
EP-1014962-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 2000-07-05 EP disclosed
WO-1999000121-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 1999-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120007-A1 Benzamide inhibitors of factor Xa TFPI, F11, F12 NR1H4 2304/4885PPARG 2764/4885F10 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.